Kevin Roarty

Kevin Roarty

Auto-generated profile, based on publicly available information

Kevin Roarty

Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2010 in Current Opinion in Pharmacology
Verified
Journal Article
Closed access
KRKevin Roarty
Kevin Roarty
JRJeffrey Rosen
Jeffrey Rosen

12 July 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
NZNa Zhao
Na Zhao
RPReid T. Powell
Reid T. Powell
XYXueying Yuan
Xueying Yuan
GBGoeun Bae
Goeun Bae
KRKevin P. Roarty
Kevin P. Roarty
JRJeffrey Rosen
Jeffrey Rosen
The epithelial-mesenchymal transition (EMT) has been implicated in conferring stem cell properties and therapeutic resistance to cancer cells. Therefore, identification of drugs that can reprogram EMT may provide new therapeutic strategies. Here, we report that cells derived from claudin-low mammary tumors, a mesenchymal subtype of triple-negative breast cancer, exhibit a distinctive organoid structure with extended “spikes” in 3D matrices. Upon a miR-200 induced mesenchymal-epithelial transition (MET), the organoids switch to a smoother round morphology. Based on these observations, we developed a morphological screening method with accompanying analytical pipelines that leverage deep neural networks and nearest neighborhood classification to screen for EMT-reversing drugs. Through screening of a targeted epigenetic drug library, we identified multiple class I HDAC inhibitors and Bromodomain inhibitors that reverse EMT. These data support the use of morphological screening of mesenchymal mammary tumor organoids as a platform to identify drugs that reverse EMT.

29 January 2014 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
JRJeffrey Rosen
Jeffrey Rosen
KRKevin Roarty
Kevin Roarty
Paracrine signaling mechanisms play a critical role in both normal mammary gland development and breast cancer. Dissection of these mechanisms using genetically engineered mouse models has provided significant insight into our understanding of the mechanisms that guide intratumoral heterogeneity. In the following perspective, we briefly review some of the emerging concepts in this field and emphasize why elucidation of these pathways will be important for future progress in devising new and improved combinatorial therapeutic approaches for breast and other solid cancers.

7 September 2022 in Molecular Biology of the Cell
Verified
Journal Article
Open access
HSHongjiang Si
Hongjiang Si
NZNa Zhao
Na Zhao
APAndrea Pedroza
Andrea Pedroza
AZAna-Maria Zaske
Ana-Maria Zaske
JRJeffrey M. Rosen
Jeffrey M. Rosen
KRKevin Roarty
Kevin Roarty
A role for Wnt/Ror2 signaling in the regulation of tumor cell-extracellular matrix interactions during cancer invasion is uncovered. The noncanonical Wnt receptor Ror2 regulates integrin-matrix adhesions, with important implications for tumor cell mechanotransduction and ECM architecture in cancer metastasis.

27 June 2023 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
HSHongjiang Si
Hongjiang Si
MEMadelyn Esquivel
Madelyn Esquivel
EMErika Mendoza Mendoza
Erika Mendoza Mendoza
KRKevin Roarty
Kevin Roarty
Breast cancer has emerged as the most commonly diagnosed cancer and primary cause of cancer-related deaths among women worldwide. Although significant progress has been made in targeting the primary tumor, the effectiveness of systemic treatments to prevent metastasis remains limited. Metastatic disease continues to be the predominant factor leading to fatality in the majority of breast cancer patients. The existence of a prolonged latency period between initial treatment and eventual recurrence in certain patients indicates that tumors can both adapt to and interact with the systemic environment of the host, facilitating and sustaining the progression of the disease. In order to identify potential therapeutic interventions for metastasis, it will be crucial to gain a comprehensive framework surrounding the mechanisms driving the growth, survival, and spread of tumor cells, as well as their interaction with supporting cells of the microenvironment. This review aims to consolidate recent discoveries concerning critical aspects of breast cancer metastasis, encompassing the intricate network of cells, molecules, and physical factors that contribute to metastasis, as well as the molecular mechanisms governing cancer dormancy.